In this edition we profile the latest new investments completed by the Maven VCTs, including biomedical data specialist Biorelate, and digital contracting platform Summize, which has developed a novel software solution for the legal sector.
Also featured is an interview with Paul Smith and Mike Piper, CEO and CCO respectively at Maven investee company BioAscent, where they discuss the evolution of the business since the Maven VCTs first invested in 2018. Last year BioAscent increased revenues by 44% and recorded its fourth successive year of high double-digit growth.
Later in the magazine, we provide an update on the positive progress made by a number of existing VCT portfolio companies which are continuing to grow despite the challenging macro-economic environment.
Finally, we highlight the current VCT Offers which will shortly close to subscriptions for this tax year. Existing shareholders and new investors have until 12 noon on 4 April to submit an application for the 2022/23 tax year.